Optimizing ART With Novel HIV Agents

In this episode, Gregory Huhn, MD, MPHTM, presents a case study of a person with a long HIV treatment history, exploring when and how to consider agents with novel mechanisms of action.

Listen as he discusses:

• The importance of engaging with patients to understand their perspectives and improve their satisfaction with their HIV care
• Options in people with multiclass resistance
• Studies of agents with novel mechanisms of action:
  • BRIGHTE (fostemsavir)
  • TMB-301/-311 (ibalizumab)
  • CAPELLA (lenacapavir)
     

Faculty

​​Gregory Huhn, MD, MPHTM,
Interim Chief, Division of Infectious Diseases
Senior Director of HIV Services
Cook County HIV Integrated Programs
Interim Medical Director, The RMR CORE Center
Professor, Division of Infectious Diseases
Rush University Medical Center
Chicago, Illinois

Follow along with the slides.
https://bit.ly/4fHmxg5

Get access to all of our new podcast episodes. Subscribe to the CCO Infectious Disease podcast on Apple Podcasts, Google Podcasts, or Spotify.    

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.